Sequence: RQIKIWFWWRRMKWKK
| Experiment Id | EXP002464 |
|---|---|
| Paper | Intraocular siRNA Delivery Mediated by Penetratin Derivative to Silence Orthotopic Retinoblastoma Ge |
| Peptide | 89WP (penetratin derivative) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Defined via charge ratio |
| Rna Concentration | 1 µg/mL siRNA (in vitro) |
| Mixing Ratio | PA N/P=2:1; 89WP:siRNA=15:1 (optimized) |
| Formulation Format | siRNA/PA/89WP polyplex |
| Formulation Components | siRNA + PAMAM G3 + 89WP |
| Size Nm | 60.00 |
| Zeta Mv | 20.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | ARPE-19; WERI-Rb-1-luci |
| Animal Model | |
| Administration Route | |
| Output Type | Gene silencing (luciferase) |
| Output Value | Near-complete luciferase knockdown vs naked siRNA |
| Output Units | |
| Output Notes | Confocal, flow cytometry uptake; functional silencing without chloroquine |
| Toxicity Notes | Cell viability >80% |
| Curation Notes |